1030892-01-3

Upstream product

• 874899-97-5 {4-[2-(2-acetamido-1,3-thiazol-4-yl)ethyl]phenyl}acetic acid 
• 530-62-1 1,1'-carbonyldiimidazole 

Relevant academic research and scientific papers

COMPOSITION FOR OPHTHALMIC DISEASE ASSOCIATED WITH HYPOXIA OR ISCHEMIA

According to the present invention, a composition containing a VAP-1 inhibitor as an active ingredient, which is effective for ophthalmic diseases associated with hypoxia or ischemia can be provided. According to the present invention, moreover, an angiogenesis inhibitor that suppresses pathologic angiogenesis associated with hypoxia or ischemia can be provided.

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CATARACT

The present invention aims to provide a pharmaceutical composition effective for the treatment of cataract. A pharmaceutical composition for the treatment of cataract, containing a VAP-1 inhibitor as an active ingredient, particularly a pharmaceutical composition for the treatment of cataract, containing a compound represented by the formula (I) and the like as an active ingredient: ????????R1-NH-X-Y-Z (I) wherein each symbol is as defined in the description.